Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17477664 | 0.83 | TSHR (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL19696362 | 0.82 | ALDH1A1 (0.36) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1839413 | 0.81 | CA12 (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL17477638 | 0.79 | GPR35 (0.41) | KDM4ETSHRKMT2APOLBALDH1A1 | |
| SCHEMBL13541632 | 0.72 | TSHR (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2399420 | 0.70 | NPC1 (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9545148 | 0.70 | POLB (0.48) | CYP1A2KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL23174424 | 0.70 | TSHR (0.62) | KDM4ETSHRGAASMN1; SMN2MEN1 | |
| SCHEMBL27984769 | 0.70 | SMN1; SMN2 (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2827984 | 0.70 | ALDH1A1 (0.59) | CYP1A2KDM4ETSHRGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240374583-A1 | USE OF MORPHINAN DERIVATIVES FOR TREATMENT OF OPIOID DELTA RECEPTOR AGONIST-RELATED DISEASE | NIPPON CHEMIPHAR CO., LTD (JP) | 2024-11-14 | — | — | US | disclosed |
| US-12109209-B2 | Use of morphinan derivatives for treatment of opioid delta receptor agonist-related disease | NIPPON CHEMIPHAR CO., LTD. (JP) | 2024-10-08 | — | — | US | disclosed |
| EP-4414037-A2 | MORPHINAN DERIVATIVES FOR THE TREATMENT OF OPIOID DELTA RECEPTOR AGONIST-RELATED DISEASES | Nippon Chemiphar Co., Ltd. (JP) | 2024-08-14 | — | — | EP | disclosed |
| EP-3513792-B9 | MORPHINAN DERIVATIVES FOR THE TREATMENT OF OPIOID DELTA RECEPTOR AGONIST-RELATED DISEASES | NIPPON CHEMIPHAR CO (JP) | 2024-07-10 | — | — | EP | disclosed |
| CN-113292559-B | Morphinan derivatives | 日本化学药品株式会社 | 2024-04-02 | — | — | CN | disclosed |
| EP-3513792-B1 | MORPHINAN DERIVATIVES FOR THE TREATMENT OF OPIOID DELTA RECEPTOR AGONIST-RELATED DISEASES | NIPPON CHEMIPHAR CO (JP) | 2024-03-27 | — | — | EP | disclosed |
| CN-117122598-A | Use of morphinan derivatives in the treatment of opioid delta receptor agonist-related diseases | 日本化学药品株式会社 | 2023-11-28 | — | — | CN | disclosed |
| CN-110248658-B | Use of morphinan derivatives in the treatment of opioid delta receptor agonist-related diseases | 日本化学药品株式会社 | 2023-10-13 | — | — | CN | disclosed |
| US-20230159530-A1 | MORPHINAN DERIVATIVE | NIPPON CHEMIPHAR CO., LTD. (JP) | 2023-05-25 | — | — | US | disclosed |
| US-11643411-B2 | Morphinan derivative | NIPPON CHEMIPHAR CO., LTD. (JP) | 2023-05-09 | — | — | US | disclosed |
| EP-1700856-B1 | THIAZOLE DERIVATIVE | KYOWA HAKKO KIRIN CO LTD (JP) | 2015-11-11 | — | — | EP | disclosed |
| US-8889718-B2 | Thiazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-11-18 | — | — | US | disclosed |
| US-20130267509-A1 | THIAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2013-10-10 | — | — | US | disclosed |
| US-8420827-B2 | Thiazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2013-04-16 | — | — | US | disclosed |
| US-20110105486-A1 | THIAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-05-05 | — | — | US | disclosed |
| US-7880013-B2 | Thiazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-20100256361-A1 | THIAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-7718808-B2 | Thiazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-05-18 | — | — | US | disclosed |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1700856-A1 | THIAZOLE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267509-A1 | THIAZOLE DERIVATIVES | THRA, CHD8, CYP2C8 | CA12 2379/4885CA1 2695/4885CA2 1889/4885 |
| US-20110105486-A1 | THIAZOLE DERIVATIVES | CHD8, CYP2C8, THRA | CA12 2638/4885CA1 3724/4885CA2 2023/4885 |
| US-11643411-B2 | Morphinan derivative | OPRM1, OPRD1, HTR2B | CA12 4206/4885CA1 2577/4885CA2 2483/4885 |
| US-20100256361-A1 | THIAZOLE DERIVATIVES | ADORA2A, ADORA3, ADORA1 | CA12 2966/4885CA1 4416/4885CA2 1302/4885 |
| US-20240374583-A1 | USE OF MORPHINAN DERIVATIVES FOR TREATMENT OF OPIOID DELTA RECEPTOR AGONIST-RELATED DISEASE | OPRD1, OPRM1, OPRK1 | CA12 4504/4885CA1 4163/4885CA2 4508/4885 |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | ADORA2A, ADORA3, ADORA1 | CA12 3306/4885CA1 4100/4885CA2 2771/4885 |
| US-12109209-B2 | Use of morphinan derivatives for treatment of opioid delta receptor agonist-related disease | OPRD1, OPRM1, OPRK1 | CA12 4504/4885CA1 4163/4885CA2 4508/4885 |
| US-20230159530-A1 | MORPHINAN DERIVATIVE | OPRM1, OPRD1, HTR2B | CA12 4206/4885CA1 2577/4885CA2 2483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.